TP53 and colorectal carcinoma: Additionally, TP53 mutations are detected in approximately 40% of CRC cases [44], yet in CSS2 tumors, characterized by a predominance of LAPTM4B+ stem‐like cells, the mutation frequency escalates to 75%.